A Review on Pathological High-risk Factors and Postoperative Adjuvant Chemotherapy in Stage IA Lung Adenocarcinoma.
10.3779/j.issn.1009-3419.2022.101.30
- Author:
Chen SHEN
1
;
Wentao FANG
1
Author Information
1. Department of Thoracic Surgery, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200030, China.
- Publication Type:Review
- Keywords:
Adjuvant chemotherapy;
Lung neoplasms;
Pathology;
Prognosis
- MeSH:
Adenocarcinoma of Lung/surgery*;
Carcinoma, Non-Small-Cell Lung/pathology*;
Chemotherapy, Adjuvant;
Humans;
Lung Neoplasms/surgery*;
Neoplasm Invasiveness;
Neoplasm Staging;
Prognosis;
Retrospective Studies;
Risk Factors
- From:
Chinese Journal of Lung Cancer
2022;25(8):593-600
- CountryChina
- Language:Chinese
-
Abstract:
The survival rate needs to be improved in early stage non-small cell lung cancer patients. The risk of recurrence is relatively high in invasive adenocarcinoma patients with a solid or micropapillary component, lymphovascular invasion or tumor spread through air spaces. Systemic treatment options including radical surgical resection should be explored for this population. Adjuvant chemotherapy is not recommended for patients in stage IA in current guidelines. This article is a review on the research progress of the above pathological high-risk factors and the role of adjuvant chemotherapy in patients with pathological high-risk factors in stage IA lung adenocarcinoma.
.
